Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC Maintenance in Ulcerative Colitis (LIBERTY-UC)
NCT04205643Phase 3Completed
- Sponsor
- Celltrion
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in ulcerative colitis (UC), sponsored by Celltrion. Started Sep 2020; status: completed.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04205643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205643.